VICL Share Price

Open 2.49 Change Price %
High 2.52 1 Day -0.03 -1.21
Low 2.45 1 Week 0.00 0.00
Close 2.45 1 Month 0.09 3.81
Volume 91178 1 Year -2.02 -45.19
52 Week High 4.59
52 Week Low 2.05
VICL Important Levels
Resistance 2 2.51
Resistance 1 2.49
Pivot 2.47
Support 1 2.41
Support 2 2.39
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Vical Incorporated (NASDAQ: VICL)

VICL Technical Analysis 2.5
As on 23rd Jun 2017 VICL Share Price closed @ 2.45 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.70 & Strong Buy for SHORT-TERM with Stoploss of 2.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
VICL Target for June
1st Target up-side 2.62
2nd Target up-side 2.75
3rd Target up-side 2.88
1st Target down-side 2.24
2nd Target down-side 2.11
3rd Target down-side 1.98
VICL Other Details
Segment EQ
Market Capital 295994240.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vical.com
VICL Address
VICL
10390 Pacific Center Court
San Diego, CA 92121
United States
Phone: 858-646-1100
Fax: 858-646-1150
Interactive Technical Analysis Chart Vical Incorporated ( VICL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vical Incorporated
VICL Business Profile
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent clinical and preclinical development programs in the areas of infectious disease and cancer, including a fully enrolled Phase III clinical trial using its Allovectin immunotherapeutic in patients with metastatic melanoma; a completed preclinical program, with an allowed investigational new drug application, using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent cytomegalovirus, infection before and during pregnancy, and a preclinical program with therapeutic and prophylactic vaccines for herpes simplex virus type II formulated with its Vaxfectin adjuvant.